URGN: UroGen Pharma Ltd Company Profile & Statistics

About

UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel.

Info & Links

CEO

Elizabeth Barrett

Headquarters

400 Alexander Park
Princeton, NJ 08540, UNITED STATES

Auditor

PricewaterhouseCoopers LLP

Share holders

Employees

201

UroGen Pharma Ltd Statistics

Valuation Measures

Market Capitalization²

257.01M

Enterprise Value

252.73M

Enterprise Value/EBITDA(ttm)

-2.96

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

2.98

Price to Book(mrq)

10.43

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

90.29%

Operating Margin(ttm)

-129.11%

Profit Margin(ttm)

-132.32%

Return on Equity(ttm)

Return on Invested Capital(ttm)

-176.38%

Return on Assets(ttm)

-47.94%

Income Statement

Revenue(ttm)

89.36M

Revenue Per Share(ttm)

2.12

Gross Profit(ttm)

80.67M

EBITDA(ttm)³

-85.25M

Net Income Available to Common(ttm)

-115.38M

Diluted EPS(ttm)

-3.15

Share Statistics

Beta (5Y Monthly)

1.06

52-Week Change

-17.78%

S&P 500 52-Week Change

26.45%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

42.20M

Dividend Yield

0.00%

Float⁴

22.26M

% Held by Insiders

5.10%

% Held by Institutions

91.29%

Balance Sheet

Total Cash(mrq)

250.65M

Total Cash Per Share(mrq)

5.94

Total Debt(mrq)

121.71M

Total Debt/Equity(mrq)

477.01%

Current Ratio(mrq)

9.00%

Quick Ratio(mrq)

8.77%

Book Value Per Share(mrq)

0.60

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.93

Free Cash Flow(ytd)

-83.33M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

URGN

UroGen Pharma Ltd

UroGen Pharma Ltd Profile